Brief: Rvl Pharmaceuticals PLC Reports Q1 2023 Financial Results, Provides Commercial Update
11/05/2023 13:54
May 11 (Reuters) - Rvl Pharmaceuticals Plc RVLP.O :
* REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS; PROVIDES
COMMERCIAL UPDATE
* QTRLY LOSS PER SHARE $0.12
* Q1 EARNINGS PER SHARE VIEW $-0.12 -- REFINITIV IBES DATA
* QTRLY TOTAL REVENUES DECREASED BY $12.6 MILLION TO $8.8
MILLION
Source text for Eikon: ID:nGNX60ppMV
Further company coverage: RVLP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RVL Pharmaceuticals
See all newsBrief: RVL Pharmaceuticals Says High Court Of Ireland Made A Winding Up Order In Respect Of Co On Feb 12
Brief: RVL Pharmaceuticals Says Co Issued Petition In Central Office Of High Court In Ireland To Wind Up Company
Brief: RVL Completes Financial Restructuring
Brief: Rvl Pharmaceuticals PLC Received Delisting Notice From Listing Qualifications Department Of Nasdaq Stock Market Llc
U.S. STOCKS ON THE MOVE-Cerevel Therapeutics, Scholar Rock, Helius